Biosyent Inc. (RX : TSX-V)
Common Stock
Follow RX
RX
Biosyent Inc.
WealthAwesomePerformance
1 Day
+1.13%
1 Week
+4.99%
1 Month
+4.37%
YTD
+40.28%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$198.81M
52W High
$18.25
52W Low
$10.49
P/E Ratio
20.82
50 Day MA
$16.49
200 Day MA
$15.05
Beta
0.70
Dividend Yield
1.21%
WA Score
How RX stacks up against 947 Canadian stocks
82
out of 99
- Value73
Earnings yield 4.7% (P/E 20.8).
- Quality73
Return on equity 23.6%, profit margin 17.7%.
- Momentum82
40.3% this year, above its 200-day average, 95% of the way up its 52-week range.
- Analysts14
Average analyst target is 0.6% above the price.
- Insiders50
0 open-market buys and 16 sales on SEDI in 180 days (net −$136K).
Each factor is a percentile against Canadian common stocks worth $50M or more on the TSX and TSX Venture (90 = better than 90% of them). Built from exchange prices, company financials, analyst targets and SEDI insider filings. A data summary, not advice. How it works · Top-scoring stocks
Performance history
RX returns since 2023
Biosyent Inc. has traded since Nov 2023 in our data, with 2 up years out of 2 full calendar years. Its deepest fall was −17.4% (Dec 2024 to Apr 2025).
1 year / yr
+65.1%
3 years / yr
+31.6%
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*+15.8%
- 2024+21.0%
- 2025+15.7%
- 2026*+40.6%
* Partial year (first year of data, or year to date).
$10,000 invested in RX
- 1 year ago$16,513
- 2023 (start of our data)$22,805
- Best year
- 2024: +21.0%
- Worst year
- 2025: +15.7%
- All-time high in our data
- $18 on Nov 9, 2026 · at the high
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past RX? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Biosyent Inc. insider transactions
Open-market and private equity trades (last 12 months volume). Derivatives and opening balances excluded.
Recent transactions
| Date | Side | Name | Shares | Price |
|---|---|---|---|---|
| Aug 26, 26 | Sell | Lockhard, Peter Douglas Individual · CA$3,926 | 246 | CA$15.96 |
| Aug 25, 26 | Sell | Lockhard, Peter Douglas Individual · CA$3,120 | 200 | CA$15.60 |
| Aug 25, 26 | Sell | Lockhard, Peter Douglas Individual · CA$4,710 | 300 | CA$15.70 |
| Jun 23, 26 | Sell | Goehrum, Rene Individual · CA$76,798 | 5,525 | CA$13.90 |
| Jun 22, 26 | Sell | Lockhard, Peter Douglas Individual · CA$1,036 | 74 | CA$14.00 |
| Jun 18, 26 | Sell | Lockhard, Peter Douglas Individual · CA$8,400 | 600 | CA$14.00 |
| Jun 11, 26 | Sell | Lockhard, Peter Douglas Individual · CA$4,200 | 300 | CA$14.00 |
| Jun 11, 26 | Sell | Lockhard, Peter Douglas Individual · CA$4,230 | 300 | CA$14.10 |
| Jun 10, 26 | Sell | Lockhard, Peter Douglas Individual · CA$4,200 | 300 | CA$14.00 |
| Jun 10, 26 | Sell | Lockhard, Peter Douglas Individual · CA$4,170 | 300 | CA$13.90 |
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/9/2026 | $17.80 | $18.25 | $17.80 | $17.90 | $17.90 | 9,081 |
| 11/6/2026 | $17.55 | $17.70 | $17.50 | $17.70 | $17.70 | 6,328 |
| 11/5/2026 | $17.39 | $17.75 | $17.10 | $17.34 | $17.34 | 12,094 |
| 11/4/2026 | $16.85 | $17.29 | $16.85 | $17.15 | $17.15 | 7,099 |
| 11/3/2026 | $17.05 | $17.10 | $16.85 | $16.85 | $16.85 | 14,543 |
| 11/2/2026 | $17.29 | $17.29 | $17.05 | $17.05 | $17.05 | 5,664 |
| 10/30/2026 | $16.90 | $17.17 | $16.90 | $17.09 | $17.09 | 5,144 |
| 10/29/2026 | $16.81 | $16.90 | $16.80 | $16.83 | $16.83 | 6,780 |
| 10/28/2026 | $16.80 | $17.40 | $16.80 | $17.00 | $17.00 | 6,970 |
| 10/27/2026 | $16.70 | $16.70 | $16.69 | $16.69 | $16.69 | 644 |
Analyst Price Targets
Based on analyst covering RX · as of Sep 17, 2026
Wall Street analysts forecast RX stock price to rise 0.6% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.00
+0.6% Upside
Current Price
C$17.90
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RX's historical volatility
30-Day Vol
31.7%
Annualized
90-Day Vol
33.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$21.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$19.00 | C$17.03 – C$21.19 |
| 60 trading days | C$20.16 | C$17.28 – C$23.53 |
| 90 trading days | C$21.40 | C$17.71 – C$25.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Financials
- Revenue (TTM)
- $55.67M
- EBITDA
- $14.88M
- Profit Margin
- 17.73%
- ROE (TTM)
- 23.65%
- EPS (Diluted)
- 0.85
- Book Value
- 4.04
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Recent Dividends
$0.0550CAD
Ex: May 29, 2026
$0.0550CAD
Ex: Feb 27, 2026
$0.0450CAD
Ex: Nov 29, 2024
$0.0450CAD
Ex: Sep 4, 2024
$0.0450CAD
Ex: May 31, 2024
$0.0450CAD
Ex: Feb 28, 2024
$0.0400CAD
Ex: Nov 29, 2023
$0.0400CAD
Ex: Aug 30, 2023
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About RX
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.